CVKD: Acquires 12-LOX Inhibitor for the Treatment of Heparin-Induced Thrombocytopenia (HIT)

CVKD READ THE FULL CVKD RESEARCH REPORT Business Update Acquires 12-LOX Inhibitor VLX-1005 for the Treatment of HIT In December 2025, Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) announced the ...
Nature

Heparin-Induced Thrombocytopenia And Its Management

Heparin-induced thrombocytopenia (HIT) is a clinically significant immune-mediated adverse reaction to heparin therapy. It is typified by a reduction in circulating platelets while paradoxically ...
The American Journal of Managed Care

EHR Alerts Improve Quality of Care in Heparin-Induced Thrombocytopenia, Study Finds

A team of researchers developed 3 quality improvement measures embedded in electronic health records (EHRs) to improve care delivery in patients with heparin-induced thrombocytopenia. HIT is known as ...

Cadrenal Therapeutics Announces Phase 2 Results with Encouraging Reductions in Thrombotic Events for CAD-1005 in HIT, Supporting Clinical Advancement

Greater than 25% absolute reduction in thrombotic events with CAD-1005 versus placebo on a background of standard anticoagulant therapy, despite ...
Business Insider

Cadrenal Therapeutics Acquires VLX-1005, a First-in-Class Phase 2 12-LOX Inhibitor for Patients with Heparin-Induced Thrombocytopenia (HIT)

Novel first-in-class therapeutic targeting a key immune signaling pathway and the underlying cause of HIT It is the first and only potent, highly selective inhibitor of human 12-LOX in clinical ...
Medscape

Heparin-Induced Thrombocytopenia Complicated by Warfarin-Induced Skin Necrosis

Purpose: A case of heparin-induced thrombocytopenia (HIT) complicated by warfarin-induced skin necrosis (WISN) is reported. Summary: A patient with a history of hypertension, heart failure, and ...
The New England Journal of Medicine

Monoclonal Antibodies in the Pathogenesis of Heparin-Induced Thrombocytopenia

Heparin-induced thrombocytopenia (HIT) is an immune-mediated platelet disorder caused by antibodies that target complexes of platelet factor 4 (PF4) and heparin. HIT has been characterized as a ...

CVKD: Phase 2 HIT Results Show Encouraging Reduction in Thrombotic Events

CVKD READ THE FULL CVKD RESEARCH REPORT Business Update Encouraging Results from Phase 2 HIT Trial On February 24, 2026, Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) announced encouraging results from ...
Medscape

Overview of Heparin-Induced Thrombocytopenia

Due to the potential for life- and limb-threatening complications, effective and immediate management of HIT is vital. When HIT is suspected, it is imperative to remove all forms of heparin, including ...
PharmiWeb

Heparin Market to Attain CAGR of 5% Valuation through 2031, Says Medi-Tech Insights in New Study

Global Heparin Market OverviewThe Global Heparin Market is projected to grow steadily at a CAGR of approximately 5% by 2026.
The New England Journal of Medicine

VITT-like Monoclonal Gammopathy of Thrombotic Significance

Vaccine-induced immune thrombocytopenia and thrombosis (VITT) is associated with antibodies that target platelet factor 4 (PF4) and are heparin-independent. VITT antibodies are implicated in acute, ...
Nasdaq

Cadrenal Therapeutics Acquires VLX-1005, a First-in-Class Phase 2 12-LOX Inhibitor for Patients with Heparin-Induced Thrombocytopenia (HIT)

PONTE VEDRA, Fla., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome the limitations of ...